S4-E4.1 - Surfing NASH Community Interview with Pamela Danagher of Terns Pharmaceuticals

Send us Fan MailIn a thematic debut, Jörn Schattenberg and Roger Green host interviews with three listeners from the Surfing NASH community to discuss takeaways from NASH-TAG 2023 and the future of Fatty Liver. The four prominent questions of each session focus around:the “straightjacket” of biopsyhow we think about “tests” when not classed as "NITs" as compared to biopsyhow do we all become better centered on patient needsthe idea of combination therapyIn this first installment, the co-hosts are joined by Pamela Danagher, Senior Vice President for Regulatory Affairs at Terns Pharmaceuticals. This conversation explores the ways that biopsy has, as Pamela puts it, constrained and restrained drug development. Not surprisingly, she also offers strong viewpoints and tremendous insights about uses of testing and combination therapy - two issues pivotal to Terns. Finally, Pamela comments briefly on what Donna Cryer described in a recent episode as “regulatory science” and how the entire community can communicate in ways that support approval of resmetirom and OCA. Each guest in these fully-featured interviews shares on-ground experiences which collectively cast invaluable light on how the information featured in Surfing the NASH Tsunami is digested and applied in everyday life. As the podcast enters its fourth season, and embarks on affiliated journeys like the Rising Tide series, we hope to grow our community engagement. If you enjoy our content, we kindly ask that you submit a review wherever you download our episodes. We also encourage our audience to write us questions and look forward to integrating your on-ground experiences and perspectives in the weekly discourse. Most important of all, we whole-heartedly thank you for your continued support as we set out to put a major dent in Fatty Liver disease in 2023 and beyond. Stay safe and surf on!